Clinical Scorecard: The New Path to ADCs

At a Glance

Key Highlights

• Tolerability is now the primary focus in ADC development, surpassing potency.
• Patients often abandon therapy due to adverse events rather than disease progression.
• The industry is shifting towards more selective payloads to improve patient outcomes.
• Repurposing failed small molecules as ADC payloads may enhance therapeutic efficacy.
• Innovative linker designs are crucial for controlling payload release and minimizing toxicity.

Guideline-Based Recommendations

Diagnosis

• Assess patient quality of life as a key factor in ADC therapy.

Management

• Prioritize the development of ADCs with improved tolerability profiles.

Monitoring & Follow-up

• Regularly evaluate patient experiences with adverse events during therapy.

Risks

• Be aware of the potential for severe adverse events that impact daily living.

Patient & Prescribing Data

Patients with various types of cancer requiring targeted therapy.

Focus on minimizing adverse events to enhance adherence to therapy.

Clinical Best Practices

• Design ADCs with a backward approach, prioritizing patient quality of life.
• Utilize advanced chemistry for linker stability and controlled payload release.
• Incorporate patient feedback into the development of new ADC therapies.

References

• World ADC London Panel Discussion